This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grundy, S. M. Search for Related Content PubMed PubMed Citation Articles by Grundy, S. M. Related Collections Cardiovascular Endocrinology Metabolism

Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor

Center for Human Nutrition, Department of Clinical Nutrition, and Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9052

Address all correspondence and requests for reprints to: Scott M. Grundy, M.D., Ph.D., Center for Human Nutrition, Department of Clinical Nutrition, and Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Y3.206, Dallas, Texas 75390-9052. E-mail: Scott.Grundy{at}UTSouthwestern.edu.

Context: The metabolic syndrome (MetS) is a multiplex risk factor for cardiovascular disease. The syndrome develops through interplay of obesity and metabolic susceptibility.

Objective: This article addresses whether the MetS construct has clinical utility.

Position: The National Cholesterol Education Program and other organizations have proposed that the MetS can be recognized clinically by a clustering of simple clinical measures including waist circumferences, blood pressure, triglycerides, high-density lipoproteins, and glucose. People with this clustering have most or all of the components of the MetS. Identifying the MetS has several advantages. It discovers persons who are at increased risk for cardiovascular disease. A diagnosis focuses more clinical attention on the underlying causes, notably obesity and other lifestyle factors; it thereby reinforces the utility of lifestyle changes in clinical practice. A diagnosis further informs physicians on choice and intensity of drug therapy for elevated cholesterol, aspirin prophylaxis, and blood pressure and glucose control. The introduction of the MetS has led to a large number of epidemiological, metabolic, and genetic studies that have heightened our understanding of the condition’s prevalence and pathogenesis. It has been a stimulus to the development of new drugs or drug combinations that will modify multiple risk factors simultaneously.

Conclusions: This author holds that the MetS counts as a multiplex cardiovascular risk factor that is clinically useful and will lead to advances in diagnosis and treatment of an important cause of cardiovascular disease.

This article has been cited by other articles:

				C. J. Glueck, Ping Wang, R. Hutchins, M. R. Petersen, and K. Golnik Ocular Vascular Thrombotic Events: Central Retinal Vein and Central Retinal Artery Occlusions Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 286 - 294. [Abstract] [PDF]

				J.-P. Despres, I. Lemieux, J. Bergeron, P. Pibarot, P. Mathieu, E. Larose, J. Rodes-Cabau, O. F. Bertrand, and P. Poirier Abdominal Obesity and the Metabolic Syndrome: Contribution to Global Cardiometabolic Risk Arterioscler. Thromb. Vasc. Biol., June 1, 2008; 28(6): 1039 - 1049. [Abstract] [Full Text] [PDF]

				I. N. Bratz, G. M. Dick, J. D. Tune, J. M. Edwards, Z. P. Neeb, U. D. Dincer, and M. Sturek Impaired capsaicin-induced relaxation of coronary arteries in a porcine model of the metabolic syndrome Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2489 - H2496. [Abstract] [Full Text] [PDF]

				C. L. Greenstone Clinician's Corner: The Metabolic Syndrome: A Lifestyle Medicine Foe Worthy of a Seek and Destroy Mission American Journal of Lifestyle Medicine, April 1, 2008; 2(2): 109 - 112. [Abstract] [PDF]

				S. M. Grundy Metabolic Syndrome Pandemic Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 629 - 636. [Abstract] [Full Text] [PDF]

				S. M. Grundy A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor Eur. Heart J. Suppl., March 1, 2008; 10(suppl_B): B16 - B23. [Abstract] [Full Text] [PDF]

				C. Natal, M. A. Fortuno, P. Restituto, A. Bazan, I. Colina, J. Diez, and N. Varo Cardiotrophin-1 is expressed in adipose tissue and upregulated in the metabolic syndrome Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E52 - E60. [Abstract] [Full Text] [PDF]

				D. C. Kem, X. Yu, E. Patterson, S. Huang, S. Stavrakis, B. Szabo, L. Olansky, J. McCauley, and M. W. Cunningham Autoimmune Hypertensive Syndrome Hypertension, November 1, 2007; 50(5): 829 - 834. [Full Text] [PDF]

				C. Ruggiero, A. Cherubini, S. S. Najjar, and L. Ferrucci Reply J. Am. Coll. Cardiol., October 30, 2007; 50(18): 1810 - 1811. [Full Text] [PDF]

				J. Gomez-Ambrosi, V. Catalan, B. Ramirez, A. Rodriguez, I. Colina, C. Silva, F. Rotellar, C. Mugueta, M. J. Gil, J. A. Cienfuegos, et al. Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3719 - 3727. [Abstract] [Full Text] [PDF]

				A. H. Friedlander and J. Weinreb Authors' response J Am Dent Assoc, June 1, 2007; 138(6): 711 - 712. [Full Text] [PDF]